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Abstract 
Acute promyelocytic leukemia (APL) is 
characterized by the clonal expansion of myeloid 
precursors blocked at promyelocytic stage and the 
presence of t(15;17)(q24;q21) resulting in the fusion 
of retinoic acid receptor alpha (RARA) gene on 
17q21.1 with promyelocytic leukemia (PML) gene 
at 15q24.1, and less frequently with other gene 
partners. Fusion between RARA and the interferon 
regulatory factor 2 binding protein 2 (IRF2BP2) 
genes is a rare variant translocation in APL. 
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Clinics and pathology 
Disease 
Acute promyelocytic leukemia (APL; FAB type M3) 
Epidemiology 
Only 3 cases to date, 2 females aged 19 and 68 years 
(Yin et al., 2015; Shimomura et al., 2016) and a 37-
years old male patient (Jovanovic et al., 2017). 
Clinics 
The 68?year?old female presented with no 
disseminated intravascular coagulation (DIC) Bone 
marrow showed marked hypercellularity with 36.8% 
promyelocytes with azurophilic granules and Auer 
rods. Immunophenotyping was positive for CD33, 
CD34, CD64, CD117 and HLA?DR (Shimomura et 
al., 2016). 
Prognosis 
The 19-year-old woman received all-trans retinoic 
acid (ATRA), arsenic trioxide and gemtuzumab 
ozogamicin and achieved complete remission but 
relapsed 10 months later (Yin et al., 2015). The other 
female patient received induction therapy with 
ATRA in comination with chemotherapy. After 
initial resistance she achieved hematological 
remission after re?induction therapy and remained in 
hematological remission for more than a year when 
she developed relapse and died 1 years later 
(Shimomura et al., 2016). The male patient was 
commenced on ATRA as a single agent and showed 
response to therapy revealing maturation of the 
leukemic blasts in bone marrows taken at day 7 and 
day 16 that was associated with normalization of the 
platelet count. Because real-time quantitative PCR 
showed persistent high level IRF2BP2/RARA fusion 
transcripts with ATRA as a single agent, 
chemotherapy was added that resulted in ongoing 
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remission 32 months from diagnosis (Jovanovic et 
al., 2017). 
Cytogenetics 
Cytogenetics molecular 
Cryptic rearrangement, detected by next-generation 
RNA-sequencing analysis followed by RT-PCR and 
direct sequencing in 1 (Yin et al., 2015), a 
paired?end mRNA sequencing followed by RT?PCR 
and direct sequencing in 1 (Shimamura et al., 2015) 
and 5' RACE-PCR in 1 case (Jovanovic et al., 2017). 
Genes involved and 
proteins 
IRF2BP2 (interferon regulatory factor 
2 binding protein 2) 
Location 
1q42.3 
Protein 
Belongs to a family of proteins that play a major role 
in the transcriptional regulation; acts as a 
transcriptional corepressor binding to the C-terminal 
repression domain of IRF2, a negative regulator of 
many interferon-responsive genes; its C-terminal 
RING-type zinc finger domain is sufficient for 
interaction with IRF2; this repression is not mediated 
by histone deacetylase activities. 
RARA (Retinoic acid receptor, alpha) 
Location 
17q21.2 
Protein 
Nuclear retinoic acid receptor; belongs to the large 
family of ligand responsive gene regulatory proteins, 
function as heterodimers with retinoid X receptors. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Transcript 
5' IRF2BP2 - 3' RARA.  
 
In the case reported by Yin et al., 2015, breakpoints 
within IRF2BP2 exon 2 and RARA intron 2 were 
detected with breakpoints at positions 1687 bp in 
IRF2BP2 and 41620 bp in RARA. Through 
alternative splicing, 2 types of fusion transcripts 
between exon 1B of IRF2BP2 and exon 3 of RARA 
that resulted in an mRNA transcript 48 bp longer 
than variant 2 were found  in a patient described by 
Shimomura et al., 2016. In the recently described 
case, fusion of exon 1 of IRF2BP2 to exon 3 of 
RARA was found (Jovanovic et al., 2017). 
Fusion protein 
Description 
The N terminal part of the fusion protein originates 
from IRF2BP2 harbouring a zinc finger motif which 
may bind DNA and the C terminal part contains 
regions mediating DNA binding, ligand binding and 
RXR heterodimerization (Shimomura et al., 2015; 
Jovanovic et al., 2017). 
Oncogenesis 
The cryptic IRF2BP2/RARA fusion shows a similar 
breakpoint within the RARA gene as in PML-RARA 
and variant RARA fusions, thus retaining DNA 
binding, RXR heterodimerization, ligand binding, 
and co-repressor and co-activator interaction 
functions of RARA. The IRF2BP2/RARA fusion 
protein is likely the central leukemia-initiating event 
in APL patients by transforming hematopoietic 
stem/progenitor cells. In co-immunoprecipitation 
assays, IRF2BP2/RARA had the capacity to self-
associate and behaved similarly to PML/RARA, 
inducing repression at retinoid response elements 
(Jovanovic et al., 2017). 
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